SCHEMBL17809574

SCHEMBL17809574

CN1CCCc2cc(-c3ccncc3)ccc21

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
GAA P10253 2/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 1/20 0.51
WDR5 P61964 1/20 0.49
NPSR1 Q6W5P4 1/20 0.46
CREBBP Q92793 3/20 0.43
HRH3 Q9Y5N1 1/20 0.43
NOTUM Q6P988 1/20 0.43
CYP11B1 P15538 6/20 0.41
CYP11B2 P19099 6/20 0.41
CYP17A1 P05093 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP19A1 P11511 1/20 0.41
GPR142 Q7Z601 1/20 0.40
CDC7 O00311 1/20 0.40
CDK9 P50750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809611 0.83 MEN1 (0.50) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL17809579 0.82 CYP11B1 (0.62) CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1
SCHEMBL8483334 0.82 CDC25A (0.50) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL17806347 0.81 NOTUM (0.46) ALDH1A1NPSR1CREBBPHRH3NOTUM
SCHEMBL17809643 0.80 CHRNA7 (0.46) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL17795410 0.79 CREBBP (0.54) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL12905356 0.78 HRH3 (0.43) WDR5HRH3CYP11B1CYP11B2CYP17A1
SCHEMBL17809556 0.78 PDK1 (0.57) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL17809777 0.78 CYP11B2 (0.48) ALDH1A1GAAMEN1MAPTHPGD
SCHEMBL17809770 0.77 WDR5 (0.51) ALDH1A1GAAMEN1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 ALDH1A1 1727/4885GAA 3371/4885MEN1 1426/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 ALDH1A1 1727/4885GAA 3371/4885MEN1 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.